Clinical Trial Update: Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia [Phase 1]

View source ↗

Summary

A Phase I clinical trial of SHR-2173 injections in patients with primary immune thrombocytopenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• SHR-2173

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: Immune Thrombocytopenia | Phase 1 | Status: RECRUITING